Fiberside Chat: When the Sun Sets on a Fiber Networking System

As companies continue to grow digitally, many successful fiber network management systems and technologies are reaching the end of their lives. But what do new technology solutions look like, and what are the risks and rewards of change? Michael Measels, VP of product management at 3-GIS, gives his insights.

When a company’s technology stack reaches the end of its life, which is when they announce that the technology or solution will no longer be supported in their programs, looking to the future is the first step.

“What we are seeing is a significant uptick in the number of conversations network providers are having with us in terms of their network management technology stack and what to do moving forward,”Measels said. “We’ve also seen in our market applications and solutions that have been in existence for decades, and as those solutions reach the end of life, change is bound to happen.”

“Organizations and the technical evaluators inside the organizations can start with the first step of realizing that they’re not repurchasing what [they] had, but rather…a new, modern way of looking at how to manage and monitor their network moving forward,” he said.

Once industries and organizations begin to re-evaluate their technologies, they should also consider how the existing workflows in this organization align to fit the new technology, “a decision that will help them maintain a forward-thinking process,” according to Measels.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More